Carolyn Myers
CEO
FT
FendX Technologies Inc.
2/10Traction
FendX Technologies develops nanotechnology-based coatings designed to reduce the spread of pathogens on surfaces. Their products aim to prevent transmission in healthcare and other industries by creating protective barriers against bacteria and viruses.
- Biotechnology
- Clean Technology
- New Materials
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
The transmission of pathogens via high-touch surfaces in healthcare, transportation, and public spaces poses a significant risk of infection, contributing to healthcare-associated infections (HAIs) and the spread of viruses. Current disinfection methods are often temporary and require frequent reapplication, leaving surfaces vulnerable to recontamination.
Solution
FendX Technologies develops nanotechnology-based coatings that prevent the adhesion and spread of bacteria, viruses, and other liquids on surfaces. Inspired by the water-resistant properties of the lotus leaf, FendX's coatings utilize a combination of nano- and micro-particles to create a surface where contaminants tend to stay on the touching object rather than transferring to the coated surface. The company's product pipeline includes REPELWRAP™ film for high-touch surfaces, spray coatings for easy application across various materials, and nano-coated catheters designed to reduce bacterial infections associated with medical devices. These coatings provide immediate and continuous protection, reducing the risk of pathogen transmission in critical environments.
Target Audience
FendX's primary customers include healthcare facilities seeking to reduce HAIs, transportation companies aiming to minimize pathogen spread, and public venues such as schools, offices, and entertainment facilities focused on creating safer environments.
Features
- REPELWRAP™ film reduces adhesion of a COVID-19 like virus, MRSA, E. coli, and B. subtilis by over 98%.
- Spray coating formulation reduces adhesion of a COVID-19 like virus and MRSA by over 98% and reduces bacterial growth by 99.7% after 8 hours.
- Nano-coated catheters reduce attachment of E. coli by over 96% after 48 hours of flow exposure and reduce blood/fibrin networks by over 95% after 24-48 hours.
- Coatings leverage a combination of nano- and micro-particles to create a repelling surface.
- The technology is exclusively licensed from McMaster University, with a growing intellectual property portfolio including licensed non-provisional national stage patent applications in multiple countries.